



Liberty Health Sciences to Open 26th Medical Cannabis Dispensary in Jacksonville Beach

Toronto, ON – July 14, 2020 — Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: [LHSIF](https://www.libertyhealthsciences.com)) (www.libertyhealthsciences.com) (“Liberty” or the “Company”), a provider of high quality cannabis announced today it plans to open its 26th medical marijuana dispensary in Florida on July 18, 2020. The new retail location in Jacksonville Beach will serve the communities of Mayport, Atlantic Beach, Neptune Beach, and Ponte Vedra Beach, subject to approval from the Florida Department of Health.

Located on the Duval County coast at 1222 South Third Street, Jacksonville Beach, FL. 32250, the dispensary is conveniently positioned along what is affectionately called northeast Florida’s “First Coast” and features a 4,700 square foot store that includes a spacious display and retail area, two private consultation rooms and an expansive waiting area. The dispensary’s operating hours are Monday through Friday, 10 a.m. to 7 p.m., Saturday, 10 a.m. to 5 p.m., and Sunday, 12 p.m. to 5 p.m. As with all Liberty locations, the Jacksonville Beach store showcases original paintings and photographs from talented, local artists on a rotating basis.

“Our expansion into the beautiful coastal resort city of Jacksonville Beach reflects not only Liberty’s rapid growth trajectory but also our commitment to providing patients accessibility and convenience to obtain quality medical marijuana throughout the state,” said Victor Mancebo, Chief Executive Officer of Liberty. “We are constantly on the lookout for the best real estate locations in Florida to provide safe access to high-quality cannabis products and services.”

During these trying times, Liberty continues to carry out best in class health and safety protocols to minimize risk to its patients, employees and facilities following local and state government health guidelines in response to the evolving COVID-19 case resurgences.

Liberty currently operates 25 dispensaries in the following locations:

- Boca Raton
- Bonita Springs
- Bradenton
- Cape Coral
- Dania Beach
- Gainesville
- Lakeland
- Palm Harbor
- Panama City
- Pensacola
- Port St. Lucie
- Sarasota
- St. Petersburg
- Stuart

- Merritt Island
- Miami
- North Miami
- Orange Park
- West Palm Beach
- Orlando
- Summerfield
- Tampa (Hyde Parke)
- Tampa (Tetra)
- Tallahassee
- Winter Haven

Patients may place an order online at www.libertyhealthsciences.com for in-store pick-up or delivery.

About Liberty Health Sciences Inc.

Liberty is the cannabis provider committed to providing a trusted, high quality cannabis experience based on our genuine care for all cannabis users and a focus on operational excellence from seed to sale. Liberty's measured approach to expansion opportunities is focused on maximizing returns to shareholders, while keeping consumers' well-being at the forefront of what we do. For more information, please visit: www.libertyhealthsciences.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release contains certain forward-looking statements within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "believe", "plan", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, expectations related to the Company's production capabilities, expectations concerning the receipt of all necessary approvals from the Florida Department of Health, expectations concerning the opening of new dispensaries and the expansion of its greenhouse space, and the Company's future expansion and growth strategies. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the medical marijuana industry in the United States generally, income tax and regulatory matters; the ability of Liberty to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions, or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Media Contacts:

Dwain Schenck
(203) 223-5230
dwain@schenckstrategies.com

Victor Mancebo
Chief Executive Officer
(352) 388-3178
VMancebo@libertyhealthsciences.com